Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 25, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the presentation of three abstracts related to the Company's pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the American Association for the Study of Liver Diseases (The Liver Meeting®). The conference will take place on November 8-12, 2019 in Boston, MA.
"We are extremely encouraged with our pre-clinical development work in evaluating our compounds as future treatments for patients with liver fibrosis, including in patients with non-alcoholic steatohepatitis, or NASH", stated Kenneth Galbraith, Chief Executive Officer. "We look forward to reporting on our progress in the development of PBI-4547, our proprietary compound, with a differentiated mechanism for the potential treatment of these diseases."
Abstracts selected for presentations are summarized below and are available on the conference website at https://www.aasld.org/education/learn-person/liver-meeting/abstracts.
Poster Presentations
PBI-4547 Restores Metabolic Homeostasis in a High Fat Diet Model of Non-Alcoholic Fatty Liver Disease: Cross-talk Between Liver and Adipose Tissue
Abstract #: 2123
Session: NAFLD and NASH Therapeutics – Pharmacologic and Other
Location: Hall B, Hynes Convention Center
Date & Time: Monday, November 11, 2019 – 8:00 am
PBI-4050 Promotes Hepatic Stellate Cell Autophagy/Mitophagy and Restores a Quiescent-Like Phenotype
Abstract # : 1451
Session: Basic Fibrosis Research and Stellate Cell Biology
Location: Hall B, Hynes Convention Center
Date & Time: Sunday, November 10, 2019 – 8:00 am
PBI-4050 Reverses Metabolic Dysregulation Induced by a High Fat Diet in a Mouse Model of Non-Alcoholic Fatty Liver Disease
Abstract # : 2136
Session: NAFLD and NASH Therapeutics – Pharmacologic and Other
Location: Hall B, Hynes Convention Center
Date & Time: Monday, November 11, 2019 – 8:00 am
About Liminal BioSciences Inc.
Liminal BioSciences (www.liminalbiosciences.com) is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, GPR40, GPR84 and GPR120, known as free fatty acid receptors (FFAR's). These drug candidates have a novel mechanism of action as agonist ("stimulator") of GPR40 and GPR 120, and antagonist ("inhibitor") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome after further consultation and approval by the FDA and EMA. A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.
Liminal BioSciences has also leveraged its lengthy experience in bioseparation technologies through its wholly-owned subsidiary Prometic BioProduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived therapeutic product is Ryplazim™ (plasminogen) for which the Company expects to file a BLA with the US FDA in the first half of 2020 seeking approval to treat patients with congenital plasminogen deficiency. The Company also operates a contract development and manufacturing operation in the United Kingdom, deriving revenue through sales of affinity chromatography media, Prometic Bioseparations Ltd.
Liminal BioSciences has active business operations in Canada, the United States, Isle of Man and the United Kingdom.
Forward Looking Statement
This presentation contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Liminal BioSciences' ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Liminal BioSciences' to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018, under the heading "Risks and Uncertainties related to Liminal BioSciences' Business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
SOURCE Liminal BioSciences Inc.
